Sangamo falls on plans to expand trial

Sangamo (NASDAQ:SGMO) fell $1.60 (14%) to $9.45 on Friday after it said it plans to expand the Phase II (SB-509-701) trial of SB-509 to treat diabetic neuropathy. The company said it completed enrollment of the originally planned 45 patients in the placebo-controlled trial evaluating 30 mg of injectable SB-509 given once in each leg on days 0 and 90 but added that it now plans to enroll another 45 patients. The additional patients will receive 30 mg SB-509 or placebo given once in each leg on days 0, 60 and 120. ...